Navigation Links
Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™
Date:6/16/2011

LA JOLLA, Calif., June 16, 2011 /PRNewswire/ -- Cebix Incorporated announced today it is advancing the development of modified C-peptide for the treatment of complications of diabetes. The biopharmaceutical company has initiated a Phase 1b clinical trial to evaluate Ersatta™, its proprietary long-acting form of C-peptide, in patients with type 1 diabetes who, because of their disease, lack this endogenous peptide.  Following the successful completion of this study, the company is planning a mid-stage clinical program in diabetic peripheral neuropathy and other chronic conditions associated with diabetes that may be reversed by replacing C-peptide.

The primary objectives of the randomized, blinded, placebo-controlled Phase 1b study are to assess the safety, tolerability as well as single and multiple dose pharmacokinetics of Ersatta after subcutaneous administration.  The study is estimated to enroll 30-60 patients and will be conducted at up to six sites in the U.S.  

Ersatta, a proprietary, mono-pegylated version of C-peptide, has improved pharmacokinetic properties compared to the native peptide. Pegylation of C-peptide extends the drug half-life, allowing for once-weekly dosing, which enhances patient compliance. Ersatta has been shown to improve nerve function in preclinical studies in a rat diabetic neuropathy model. Cebix has defined the pathway to marketing approval for Ersatta under U.S. Food and Drug Administration (FDA) subpart H. Nerve conduction velocity will therefore be the sole primary endpoint for a Phase 2/3 pivotal trial in diabetic peripheral neuropathy, which Cebix plans to initiate in the first half of 2012. Cebix has been granted fast track status by FDA for Ersatta in the diabetic peripheral neuropathy indication.

To date, Cebix has raised $30.5 million in Series A financing and established a database of 19 clinical studies evaluating native C-peptide in more than 300 patients with ty
'/>"/>

SOURCE Cebix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4%, 30 mL Single Dose Vial Due to Particulates
2. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
3. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. American Regent Initiates Nationwide Voluntary Recall of Sterile Water for Injection, USP, 50 mL Single Dose Vial Due to Particulate Matter
6. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
7. BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
8. Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
9. Independent Investigator Initiates Phase 1 Study of Biodels Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps
10. American Regent Initiates Nationwide Voluntary Recall of Caffeine & Sodium Benzoate Injection, USP 250 mg/mL, 2 mL Single Dose Vial Due to Visible Particulates
11. Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... The current model for care of people with ... could bring devastating consequences not only the United States ... as diabetes is now the most significant public health ... On the crux of Diabetes Awareness Month, three ...
... Technologies, a developer and manufacturer of custom fluid-handling components ... a new range of hydrophilic, polyurethane foams for Advanced ... fair in Dusseldorf, Germany from 16 to 18 November ... New innovations to be featured at the show ...
Cached Medicine Technology:Global Trend in Diabetes Could Exact Catastrophic Toll on Emerging Global Healthcare Systems 2Global Trend in Diabetes Could Exact Catastrophic Toll on Emerging Global Healthcare Systems 3Global Trend in Diabetes Could Exact Catastrophic Toll on Emerging Global Healthcare Systems 4Filtrona Porous Technologies to Introduce New Hydrophilic Foam Products for Advanced Wound Care at the MEDICA / COMPAMED Trade Fair 2
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... published in the August issue of the American Journal ... multidetector computed tomography (MDCT) in diagnosing// the spread of ... MDCT on 69 patients to examine the efficiency of ... of the 44 cases, while MDCT correctly diagnosed 27. ...
... at a local hospital in Tulungagung, East Java, became ... yesterday.// Runizar Ruesin from the health ministry's bird flu ... with dead chickens. ,Local tests confirmed that ... to deal with bird flu infection and the human ...
... September is the World Heart Day. The theme for the ... all, especially the youth//, to follow a health-friendly regime and ... ,A healthy heart is the foundation to a healthy ... to a healthy life. The booming IT industry, with its ...
... of Fresno, is going through a rough patch, following a ... was enforced after three children from South California took ill ... the State’s charge said "There's a lot of confusion. The ... it's an over-reaction." , ,The State Department of Food ...
... to focus more on healthy eating could be accomplished ... children to eat healthier food could lead to clashes ... has been unveiled by the government which is aimed ... to shorter life expectancies in the younger generation than ...
... Health & Science University's (OHSU) Doernbecher Children's Hospital, the ... to cure Batten disease// is set to get underway ... but deadly neurodegenerative disorder. A phase I trial is ... of its efficacy.,According to the researchers, the transplants of ...
Cached Medicine News:Health News:Healthy Heart for a Hearty Life 2Health News:$67m to Tackle Obesity 2Health News:Stem cell trial to beat Batten Disease 2Health News:Stem cell trial to beat Batten Disease 3
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
This forcep was designed to eliminate the occasional tearing of tissue which may occur when grasping the lips of an incision with a traditional. 12 forceps. The rows of blunt teeth are gentle yet pro...
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with 90 degrees, 2 x 3 teeth and tying platform. Serrated handle with polished finish. Most popular size or model....
Medicine Products: